… of both obesity and polypharmacy in NVAF patients, this … of NVAF patients with both obesity
and polypharmacy. The … bleeding overall among NVAF patients with obesity and one or …

… multimorbidity and polypharmacy contributes to the complexity of management among
individuals with AF and (2) identify any interventions to manage polypharmacy in relation to AF. …

… atrial fibrillation (NVAF) patients with obesity and polypharmacy… patients with obesity (BMI
≥30 kg/m 2 ) and polypharmacy (≥5 … among NVAF patients with obesity and polypharmacy in …

… among anticoagulant users with obesity are currently scarce … of NVAF patients with obesity
and polypharmacy in the US. We … for NVAF patients with obesity and polypharmacy compared …

… patients with polypharmacy. … patients with and without polypharmacy; (2) assessing the
effectiveness and safety outcomes of NOACs versus VKAs in patients with AF and polypharmacy; …

… Indeed, the rate of polypharmacy in AF patients can be as high as 76.5%. Polypharmacy
is associated with negative clinical outcomes including potentially serious drug–drug …

… and AF treatments in a large sample of AF patients aged ≥75 years … patients receiving
polypharmacy are more likely to have an adverse outcome than those not receiving polypharmacy…

… Previous evidence indicated that atrial fibrillation (AF) patients with polypharmacy presented
… of polypharmacy, risk factors for polypharmacy, and the impact of polypharmacy in clinical …

… This thesis examines polypharmacy in atrial fibrillation (AF). The rationale for … to obesity
and polypharmacy, are important because Public Health England (PHE) have identified obesity …

… This study also confirms our previous research into the factors associated with
polypharmacy, by showing that lower wealth and obesity were significantly associated with …